Infection-related hospitalizations in breast cancer patients: Risk and impact on prognosis
Introduction
Breast cancer is the most common malignancy diagnosed in women worldwide and the number of prevalent cases is increasing due to the overall rise in breast cancer incidence and improved survival rate.1 As a result of the increased life expectancy, morbidity after a breast cancer diagnosis has become more important from a clinical and public health perspective.2 Infections are a common complication in breast cancer patients and result from immunosuppression due to treatment and the malignancy itself.3, 4 Most infections are transient in nature, but their consequences may last longer. Severe infections, for instance, have been associated with prolonged hospitalization and treatment delay,5, 6 and are a major cause of future morbidity and mortality.3, 7
Despite the considerable impact on patient outcome and health care use, limited data are available on the incidence of serious infections in breast cancer patients. Previous studies have primarily focused on infection-related hospitalizations during periods of chemotherapy-induced neutropenia8, 9 and data beyond the initial treatment period are scarce. Moreover, breast cancer and its treatment may predispose to infections at certain organ sites, but no studies to date have reported risk estimates for site-specific infections. Also, little is known about the tumor and treatment dependent risk profile and the impact of infection-related hospitalizations on mortality.
In the present study we aimed to assess the risk and prognostic implications of serious infections in breast cancer patients. Using registry-based data, we studied the incidence of infection-related hospitalizations in breast cancer patients as compared to the general female population, by time since diagnosis. We also examined associations with patient, tumor and treatment characteristics as well as the impact of infection-related hospitalizations on overall and breast cancer-specific survival.
Section snippets
Study population
The Stockholm Gotland Breast Cancer Register is a population-based clinical register recording all breast cancer diagnoses occurring in the Swedish counties of Stockholm and Gotland since 1976. The register has more than 95% completeness for women aged less than 75 years at diagnosis and contains detailed information on tumor characteristics and primary breast cancer treatment, as well as routine follow-up information on locoregional recurrence and distant metastasis.10, 11 For the present
Results
Descriptive characteristics of the breast cancer cohort are summarized in Table 1. Mean age at diagnosis was 57.4 years and the median length of follow-up was 4.9 years. In total, 720 patients experienced an infection-related hospitalization following diagnosis. When comparing rates of site-specific infections, respiratory infections and sepsis were most frequently reported. The largest group of other infections was unspecified and not classifiable according to organ site (Supplementary Table S2
Discussion
Infections are a common cause of hospitalization in breast cancer patients, but estimates of the actual risk and prognostic implications of infection-related hospitalizations are scarce. This is the first study reporting risk estimates by time since diagnosis and infection site. In total, 720 patients experienced an infection-related hospitalization during a median follow-up of 4.9 years. Infection rates were highest within the first year of diagnosis, and site-specific risks were most
Conflicts of interest
The authors declare no conflict of interest.
Author contributions
Study concept and design: JSB, EC, PH, KC.
Acquisition, analysis or interpretation of data: All authors.
Statistical analyses: JSB, ALVJ, MC.
Drafting of the manuscript: JSB, KC.
Critical revision and approval of the manuscript: All authors.
Acknowledgments
This work was financed by the Swedish Research Council (grant no: 2014-2271); the Swedish Cancer Society CAN (grant no: 2013-469) and FORTE (grant no: 2013-0474). The funders had no role in the study design; in the collection, analysis, and interpretation of the data; or the decision to submit the manuscript for publication. The study sponsors had no role in the design of the study, the collection, analysis or interpretation of the data, the writing of the manuscript or the decision to submit
References (34)
- et al.
Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis
Lancet
(2011) - et al.
Nosocomial infections in patients with cancer
Lancet Oncol
(2009) - et al.
Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors
Crit Rev Oncol Hematol
(2005) - et al.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
J Chronic Dis
(1987) - et al.
The epidemiology of sepsis in patients with malignancy
Chest
(2006) - et al.
Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer
Lancet Oncol
(2004) - et al.
Reduced lymphocyte transformation in breast cancer
Lancet
(1971) - et al.
The association between infections and chemotherapy interruptions among cancer patients: prospective cohort study
J Infect
(2015) - et al.
Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer
J Clin Oncol
(2005) Epidemiology of infections in cancer patients
Cancer Treat Res
(2014)
Hospitalizations for infection in cancer patients: impact of an aging population
Support Care Cancer
Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients
Br J Cancer
Current epidemiology and prevention of infectious complications in cancer patients
Eur Oncol Haematol
Surveillance for hospitalizations with infection-related diagnoses after chemotherapy among breast cancer patients diagnosed before age 65
Chemotherapy
Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study
Breast Cancer Res Treat
Undernotification of diagnosed cancer cases to the Stockholm Cancer Registry
Int J Epidemiol
External review and validation of the Swedish national inpatient register
BMC Public Health
Cited by (26)
MicroRNA-432 Acts as a Prognostic Biomarker and an Inhibitor of Cell Proliferation, Migration, and Invasion in Breast Cancer
2021, Clinical Breast CancerCitation Excerpt :Breast cancer is a heterogeneous disease that is caused by many risk factors.3,4 To identify the risk factors of breast cancer is not only of great significance for the prevention of breast cancer but also can provide a basis for the screening of risk factors in high-risk breast cancer groups, thus individual-based therapy with early diagnosis and treatment can enable the patients to obtain a good prognosis.5 With the improvement of breast cancer screening, diagnosis, and treatment strategies, the early diagnosis and effective treatment of breast cancer have been greatly improved.6
A novel risk classifier to predict the in-hospital death risk of nosocomial infections in elderly cancer patients
2023, Frontiers in Cellular and Infection MicrobiologyThe role of microglia in 67NR mammary tumor-induced suppression of brain responses to immune challenges in female mice
2023, Journal of NeurochemistryHow can an immunologist infl uence the occurrence of secondary infections in breast cancer? Real-life study
2023, Bratislava Medical Journal